While several groups have explored the targeting of oncolytic viruses to take advantage of EGFR upregulation in cancer for increased therapeutic specificity,43, 44, 45 EGFR inhibitors have not typically been explored to modulate oncolytic virotherapy efficacy. The gene discussed is EGFR; the disease is cancer.